Recognizing 100 Years of Thrombotic Thrombocytopenic Purpura
Rare Blood DisordersOver the last century, the understanding and treatment of TTP have evolved significantly. We are proud of the part we play in addressing unmet needs for people living with TTP.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare, immune-mediated blood disorder that causes small blood clots in blood vessels throughout the body. These clots can cause serious health problems, including bruising, low platelet count, and organ dysfunction that can result in serious events like seizures, heart attacks, or strokes.
100 years ago, TTP was first described by a physician. As we reflect on the years of progress in understanding TTP, we’re proud of our role in furthering treatment options for patients.
At Sanofi, we chase the miracles of science to improve people’s lives and our dedication to the TTP community is evidence of that pursuit.